Welcome to our dedicated page for Axt SEC filings (Ticker: AXTI), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The AXT, Inc. (AXTI) SEC filings page brings together the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. As a Nasdaq-listed issuer, AXT submits periodic and current reports that describe its financial condition, operations and material events related to its business of developing and manufacturing compound and single element semiconductor substrate wafers.
Through this page, investors can access annual reports on Form 10-K and quarterly reports on Form 10-Q, which provide detailed financial statements, management discussion and analysis, and information about AXT’s substrate products based on indium phosphide, gallium arsenide and germanium. These filings also describe risk factors, business segments, manufacturing footprint in China and the role of its subsidiary Beijing Tongmei Xtal Technology Co., Ltd.
AXT’s current reports on Form 8-K document material events such as quarterly earnings announcements, preliminary revenue ranges, export control developments affecting indium phosphide and gallium arsenide shipments, capital-raising transactions under its Form S-3 shelf registration statement, and corporate governance matters including board changes and Nasdaq listing rule compliance. Some 8-Ks incorporate press releases as exhibits, giving additional context to the headline events.
Investors can also review registration statements and prospectus supplements related to AXT’s public offerings of common stock, which outline the terms of the offerings and the company’s stated use of proceeds, including plans to increase manufacturing capacity at Tongmei, fund research and development and support general corporate purposes.
On Stock Titan, AI-powered tools summarize lengthy filings, highlight key sections and help explain complex topics such as revenue drivers, export control impacts, capital structure changes and audit committee disclosures. Real-time updates from EDGAR ensure that new AXTI filings, including Forms 10-K, 10-Q, 8-K and registration-related documents, are available promptly, while insider transaction reports on Form 4 can be monitored alongside these core filings.
AXT, Inc. is offering 8,560,311 shares of common stock pursuant to this prospectus supplement, with a 30-day option to purchase up to 1,284,046 additional shares. The public offering price is $64.25 per share, with estimated gross proceeds of $550.0M before underwriting discounts and expected delivery on or about April 22, 2026, subject to customary closing conditions. Net proceeds are intended to support subsidiary Tongmei’s InP capacity expansion, R&D, working capital and general corporate purposes. The prospectus highlights export-permit risks for indium phosphide substrates from China and notes that permits to ship to the United States are in final stages of review.
AXT, Inc. entered into an underwriting agreement for a public offering of 8,560,311 shares of common stock at $64.25 per share, targeting gross proceeds of about $550 million before expenses. Underwriters have a 30-day option to buy up to 1,284,046 additional shares, which would raise total gross proceeds to roughly $632.5 million.
The cash is intended mainly to fund Beijing Tongmei Xtal Technology Co., Ltd. as it expands indium phosphide substrate capacity, along with research and development, working capital and general corporate purposes. A 60-day lock-up applies to directors and executive officers, and the deal uses AXT’s automatic shelf registration on Form S-3.
AXT, Inc. released preliminary estimates for its results for the three months ended March 31, 2026. The Company anticipates revenue between $26 million and $28 million. It expects a net loss attributable to the Company between $1.6 million and $2.6 million, or a basic and diluted net loss per share between $0.03 and $0.05. These figures are based on management’s initial review and may change once full financial closing procedures are completed and the formal Form 10-Q is issued.
AXT, Inc. is offering shares of its common stock under an automatic shelf registration, via a preliminary prospectus supplement dated April 20, 2026, to certain institutional investors. The offering is subject to completion and customary closing conditions.
The company states the net proceeds will be used to support its PRC subsidiary Tongmei’s capacity expansion for indium phosphide substrates for export, for research and development, and for working capital and general corporate purposes. AXT notes all manufacturing is performed in the PRC by its PRC subsidiaries and joint ventures, and it transfers cash within the corporate structure via capital contributions, royalties/fees, transfer-pricing purchases, and dividends.
AXT discloses that Tongmei has obtained export permits for indium phosphide shipments to Europe, Japan, the UK and Canada; U.S. export permits are in final review but not yet issued. The supplement highlights legal and operational risks tied to PRC regulations, export controls including the revised Foreign Trade Law, and cautions that export-permit timing could affect revenue recognition under U.S. GAAP.
AXT, Inc. filed a Form S-3 shelf registration to permit the sale, from time to time, of common stock, warrants and units. The prospectus describes general terms and states that specific amounts, prices and net proceeds will be set in prospectus supplements. The company notes all manufacturing occurs in the People’s Republic of China through PRC subsidiaries and joint ventures and discloses supply‑chain, dividend and PRC regulatory risk information.
AXT, Inc. is asking stockholders to approve several key items at its May 14, 2026 annual meeting, including electing two Class I directors, an advisory vote on executive pay, ratifying BPM LLP as auditor, and an amendment to increase authorized common stock from 70,000,000 to 120,000,000 shares.
Holders of 55,578,599 shares of common stock as of March 20, 2026 can vote in person or by proxy, with most materials delivered online to reduce costs. The board, led by CEO and Chair Dr. Morris Young and lead independent director Jesse Chen, highlights its independent committees, performance‑linked cash bonuses and performance‑based restricted stock awards, and recommends voting FOR all proposals, including the adjournment authority if more time is needed to secure approval of the share increase.
AXT, Inc. is soliciting proxies for its annual meeting of stockholders to be held on May 14, 2026 at its Fremont, California offices. Registered holders of common stock as of March 20, 2026 (55,578,599 shares outstanding) may vote.
Agenda items include election of two Class I directors, an advisory say-on-pay vote, ratification of BPM LLP as auditor, and a proposal to amend the Restated Certificate of Incorporation to increase authorized common shares from 70,000,000 to 120,000,000 in substantially the form attached as Appendix A. The Board recommends a vote FOR all proposals.
AXT, Inc. is a materials science company that manufactures high‑performance semiconductor substrates—indium phosphide (InP), gallium arsenide (GaAs) and germanium (Ge)—entirely in China through subsidiaries and joint ventures. These wafers serve data centers, 5G infrastructure, fiber optics, LEDs, lasers and solar cells, with InP closely tied to AI‑driven high‑speed data transmission.
The company runs a vertically integrated supply chain for key raw materials like high‑purity gallium, arsenic, germanium and pBN crucibles, giving cost and sourcing advantages. Substrates provided 67% of 2025 revenue, with raw materials at 33%. International sales dominate: 98% of 2025 revenue came from outside North America.
AXT highlights significant geopolitical and regulatory exposure. All wafers are made in China, and exports face evolving Chinese permit regimes and U.S.–China trade frictions. U.S. tariffs on its wafer imports rose to 70% in 2025, contributing to North America revenue falling from 8% of total in 2024 to about 2% in 2025. A February 2026 U.S. Supreme Court decision invalidated many IEEPA‑based tariffs, though key Section 232 and 301 tariffs remain. The company also depends on Chinese approvals for Tongmei’s planned STAR Market IPO, where investors hold a 7.28% redeemable noncontrolling interest of about $49 million.
AXT Inc. director Jesse Chen reported selling AXT common stock in two open-market transactions. On March 12, 2026, he sold 6,003 shares at a weighted-average price of $48.9541 per share, leaving 117,609 shares held directly after that trade.
On March 13, 2026, he sold an additional 8,083 shares at a weighted-average price of $50.2497 per share, resulting in 109,526 shares of AXT common stock held directly following the transactions. The filing notes both prices are weighted averages across multiple trades within disclosed price ranges.
AXT Inc. CEO Morris S. Young reported an indirect sale of 37,905 shares of AXT common stock on March 13, 2026, executed by the Young Family Trust DTD. The open-market sale occurred at a weighted average price of $51.1283 per share, with individual trades ranging from $50.87 to $51.45. Following the transaction, the reported indirect holdings stood at 2,275,328 shares of common stock.